The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Safeway Fundraising Campaign Advances Reductions in Prostate Cancer Mortality

<p class=' bwtextaligncenter'> <i><b>Prostate Cancer Foundation Cites Company for “Making a Tremendous Difference” in Accelerating Scientific Discovery for New Treatments and Ultimately a Cure</b></i> </p>

Tuesday, June 01, 2010

Safeway Fundraising Campaign Advances Reductions in Prostate Cancer Mortality13:49 EDT Tuesday, June 01, 2010 PLEASANTON, Calif. (Business Wire) -- Safeway Inc. (NYSE:SWY) launched its annual prostate cancer fundraising and awareness campaign today to fight the most prevalent form of cancer in men. This will be the tenth year Safeway has dedicated an entire month to supporting prostate cancer research. Since 2001, the company and its customers have raised more than $54 million to fund Prostate Cancer Foundation (PCF) cancer research. Safeway's annual campaign has played a key role in significantly raising awareness and funding for research—two factors that have helped reduce the prostate cancer mortality rate. In the past twelve years, prostate cancer death rates have fallen from nearly 40,000 annually to 27,000 today. The numbers are noteworthy because they have declined as baby boomers age and become more vulnerable to the disease. Safeway is PCF's single largest corporate supporter raising funds for prostate cancer research. According to PCF, Safeway's efforts have made significant contributions in accelerating scientific discovery for new treatments and ultimately a cure. Some of the achievements made possible with the support of Safeway, its employees and customers include the development of innovative medications, vaccines that signal the body's immune system to fight cancer, and the identification of specific gene fusions that initiate numerous prostate cancers. The identification of these fusions can be used for better diagnostics and treatment decisions. Funds raised by the Safeway campaign are also driving the development of a promising new therapy that utilizes nanoparticles and non-harmful magnetic waves to heat prostate tumors, making them more responsive to treatments. “In the past decade, the progress made in finding better treatments for prostate cancer is the most measurable of any cancer research,” said PCF President and CEO, Jonathan W. Simons, MD. “Safeway customers and employees can take pride in knowing they are making a tremendous difference toward bringing an end to the suffering that comes as a result of prostate cancer.” According to PCF, 1 in 6 men in the United States are affected by prostate cancer. It is the most common non-skin cancer in America, with the likelihood of being stricken with the disease increasing with age. In fact, about 65 percent of all prostate cancers are diagnosed in men over the age of 65. However, the disease is highly curable through early detection and effective treatment. “We remain committed to funding research and making a meaningful impact in the quest for new treatments and, ultimately, a cure,” said Safeway Chairman, President and Chief Executive Officer Steve Burd. “Our June campaign will raise funds for research and awareness about the importance of early detection and treatment to the millions of consumers who come through our stores daily.” Safeway will reach its customers through a series of in-store communication vehicles during June. Each June, the company's U.S. and Canadian stores give customers the chance to make donations at the checkstand when shopping at their local Safeway, Dominick's, Randalls, Tom Thumb, Genuardi's, Vons, Pavilions, Carrs and Pak n' Save stores. The funds raised are donated in the form of research grants to some of the most respected teaching and research hospitals in North America: Fred Hutchinson Cancer Center in Seattle Johns Hopkins University in Baltimore The University of California, San Francisco M.D. Anderson Cancer Center in Houston The University of British Columbia An example of the research funded by Safeway is an innovative program being led by Drs. Robert Getzenberg and Theodore DeWeese of The Johns Hopkins University School of Medicine in partnership with researchers from MIT, Dana-Farber Cancer Institute, the University of Michigan and The Prostate Cancer Center of Vancouver, Canada. The goal of this program is to increase patient response to a variety of therapies — including chemotherapy, radiotherapy and immunotherapy — by injecting nanoparticles into the patient. The nanoparticles collect in tumors and can be heated, using an external magnetic field, which weakens the tumor and makes it more responsive to therapy. This project has moved rapidly from concept to prototype and is now being tested in the laboratory. Safeway's support of PCF research programs is also helping to make important advances in other areas. Just two examples are immunotherapy (the science of stimulating a patient's own immune system to destroy cancer cells) and new blood-and urine-based diagnostic tools. These “liquid biopsies,” which are cancer-specific and can also help measure patient response to treatment, are now on the horizon. Safeway is one of the largest corporate supporters of cancer causes, having raised nearly $131 million for breast and prostate cancer research and treatment since 2001. However, cancer research is just one of the many important causes that the company supports each year. Safeway contributes to a broad range of charitable and community programs and in 2009 donated more than $253 million to education, hunger relief, health and human services and programs focused on assisting people with disabilities. About Safeway Safeway Inc. is a Fortune 100 company and one of the largest food and drug retailers in North America, based on sales. The company operates 1,712 stores in the United States and western Canada and had annual sales of $40.8 billion in 2009. The company's common stock is traded on the New York Stock Exchange under the symbol SWY. About the Prostate Cancer Foundation The Prostate Cancer Foundation is the world's largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for recurrent prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 research projects at nearly 200 institutions worldwide. The PCF also advocates for greater awareness of prostate cancer and more governmental research funds. PCF advocacy has helped produce a 20-fold increase in government funding for prostate cancer since 1994. More information about prostate cancer and the PCF can be found at